OMONTYS
Clinical safety rating
cautionComprehensive clinical and safety monograph for OMONTYS (OMONTYS).
Erythropoiesis-stimulating agent; synthetic peptide agonist of the erythropoietin receptor (EPOR) that stimulates erythropoiesis in red blood cell precursors.
| Metabolism | Not metabolized by cytochrome P450 enzymes; degraded into small peptides and amino acids via catabolic pathways. |
| Excretion | Primarily eliminated via the reticuloendothelial system; no significant renal or biliary excretion. The iron component is incorporated into hemoglobin or stored as ferritin/hemosiderin. |
| Half-life | Terminal elimination half-life is approximately 14.5 hours in healthy adults; in hemodialysis patients, half-life is extended to 26.4–29.9 hours, supporting weekly dosing. |
| Protein binding | Ferric pyrophosphate citrate moiety: <5% bound to plasma proteins; iron is rapidly transferred to transferrin. |
| Volume of Distribution | Vd approximately 0.47 L/kg (range 0.2–0.8 L/kg), indicating distribution primarily into plasma and interstitial fluid; iron distributes to bone marrow and reticuloendothelial system. |
| Bioavailability | Not applicable; OMONTYS is administered only intravenously. Oral bioavailability is not relevant. |
| Onset of Action | Intravenous administration: hemoglobin rise observed within 1–2 weeks; reticulocyte count increase within 7–10 days. |
| Duration of Action | Hemoglobin levels maintained for up to 4 weeks following a single IV dose; weekly dosing regimen sustains correction of iron deficiency anemia in hemodialysis patients. |
| Molecular Weight | 45000 |
45 mg subcutaneously once every 4 weeks (monthly) in adults.
| Dosage form | SOLUTION |
| Renal impairment | No dosage adjustment required for any degree of renal impairment, including end-stage renal disease. |
| Liver impairment | No dosage adjustment recommended for mild or moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C). |
| Pediatric use | Safety and efficacy in pediatric patients have not been established; no recommended dose. |
| Geriatric use | No specific dosage adjustment needed; consider age-related renal function and individual tolerability. |
| 1st trimester | Limited human data. Animal studies show embryo-fetal toxicity. Use only if benefit outweighs risk. |
| 2nd trimester | Limited human data. Based on mechanism, potential for fetal harm. Monitor for maternal hypertension and thrombotic events. |
| 3rd trimester | Limited human data. Use only if clearly needed. May increase risk of thrombotic events and hypertension. |
Clinical note
Comprehensive clinical and safety monograph for OMONTYS (OMONTYS).
| Placental transfer | Based on molecular weight and animal studies, omontys is expected to cross the placenta. Embryo-fetal toxicity observed in animal studies. |
| Breastfeeding | It is unknown if omontys is excreted in human milk. Because of the potential for adverse reactions in the breastfed infant, breast-feeding is not recommended during treatment and for at least 2 weeks after the last dose. |
| Lactation Rating | L5 |
| Teratogenic Risk | OMONTYS (pegcetacoplan) is a complement inhibitor. There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, no adverse developmental effects were observed at maternal exposures up to 20 times the human exposure at the recommended clinical dose. Based on its mechanism of action as a complement inhibitor, there is a theoretical risk of increased susceptibility to infections for the fetus, but no specific teratogenic effects have been identified. The drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. |
| Fetal Monitoring | Monitor for signs and symptoms of infection, including encapsulated bacteria (e.g., Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae). Fetal monitoring with standard prenatal care (ultrasound, fetal growth assessment) is recommended. Ensure appropriate vaccination status (e.g., meningococcal vaccine) prior to conception if possible. Monitor maternal complement activity and complete blood count (CBC) as per usual clinical practice. No specific fetal monitoring beyond routine obstetric care is indicated. |
| Fertility Effects | There are no human data on the effect of pegcetacoplan on fertility. In animal studies, no adverse effects on male or female fertility were observed at exposures up to 20 times the human exposure. The drug is not expected to impair fertility based on its mechanism of action, but these data are limited. |
■ FDA Black Box Warning
Increased risk of serious cardiovascular events, myocardial infarction, stroke, venous thromboembolism, vascular access thrombosis, and mortality when targeting hemoglobin levels >11 g/dL; increased risk of tumor progression and recurrence in patients with cancer; not indicated for treatment of anemia in cancer patients due to increased risk of death and serious cardiovascular events.
| Serious Effects |
Hypersensitivity to omontys or any component of the formulationUncontrolled hypertension
| Precautions | Increased mortality, serious cardiovascular events, and thromboembolic events; hypertension; seizures; pure red cell aplasia (PRCA) with neutralizing antibodies; increased risk of tumor progression in cancer patients; hemoglobin monitoring; iron deficiency management; hypersensitivity reactions including anaphylaxis. |
| Food/Dietary | No clinically significant food interactions reported. Administer subcutaneously, independent of meals. |
| Clinical Pearls | OMONTYS (pegcetacoplan) is a C3 inhibitor approved for paroxysmal nocturnal hemoglobinuria (PNH). Initiate only in patients vaccinated against encapsulated bacteria (Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae type b) due to increased infection risk. Monitor for hemolysis, thrombosis, and breakthrough disease; consider dose adjustments if hemoglobin drops significantly. Do not discontinue abruptly—switch to alternative therapy under medical supervision. |
| Patient Advice | You must receive vaccinations against meningococcus, pneumococcus, and Haemophilus influenzae type b before starting OMONTYS and maintain up-to-date immunizations. · Report any signs of infection immediately: fever, headache with stiff neck, confusion, chills, or rash. · Do not stop taking OMONTYS without talking to your doctor—sudden discontinuation may cause serious hemolysis. · You may experience injection site reactions; rotate injection sites and avoid injecting into tender or scarred areas. · Store OMONTYS in the refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze or shake. Protect from light. |
Loading safety data…